TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Jan 27, 2023 11:46 JST
Source:
Eisai
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
TOKYO and CAMBRIDGE, Mass., Jan 27, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril* antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology, for review following a standard timeline.
In the U.S., lecanemab was granted accelerated approval as a treatment for AD by the U.S. Food and Drug Administration (FDA) on January 6, 2023. On the same day, Eisai submitted a Supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway based on the results from the Phase III Clarity AD confirmatory study. In Japan, Eisai submitted a marketing authorization application to the Pharmaceuticals and Medical Devices Agency (PMDA) on January 16, 2023. In China, Eisai has initiated submission of data for a BLA to the National Medical Products Administration (NMPA) of China in December 2022.
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
*Protofibrils are large Aβ aggregated soluble species of 75-500 Kd.(1),(2)
(1) "Lecanemab Sweeps up Toxic AΒ Protofibrils, Catches Eyes of Trialists." ALZFORUM, ALZFORUM, 21 Nov. 2021, bit.ly/3HzXXyE.
(2) Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, Lannfelt L, Pettersson FE. Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation. PLoS One. 2012;7(2): e32014. doi: 10.1371/journal.pone.0032014. Epub 2012 Feb 15. PMID: 22355408; PMCID: PMC3280222.
For more information, visit www.eisai.com/news/2023/news202311.html.
Source: Eisai
Sectors: BioTech
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024
September 05 2024 15:59 JST
Eisai Announces Status Relating to Acquisition of Own Shares
September 02 2024 14:12 JST
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
August 22 2024 18:54 JST
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates
August 14 2024 08:59 JST
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation
August 06 2024 12:15 JST
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024
July 31 2024 12:59 JST
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
July 29 2024 16:59 JST
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
July 25 2024 09:30 JST
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024
July 23 2024 19:23 JST
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel
July 12 2024 11:56 JST
More Press release >>
Latest Press Release
TANAKA Precious Metals Announces Executive Appointments
Sep 07, 2024 03:00 JST
Panasonic Energy and Mazda to Begin Preparation for Supply of Automotive Lithium-ion Batteries
Sep 06, 2024 16:34 JST
Toyota's Next-Generation BEV Battery Development and Production Plan Certified by METI
Sep 06, 2024 15:10 JST
Toyota Motor Corporation and BMW Group Strengthen Collaboration Towards the Advancement of a Hydrogen Society
Sep 06, 2024 09:26 JST
DENSO Fukushima Launches Production of Inverters
Sep 05, 2024 17:41 JST
Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024
Sep 05, 2024 16:59 JST
Launch of IOWN Network Solution for 400Gbps High-Speed Inter-Data Center Connections that Reduces Construction and Operation Costs by 50%, and power consumption by 40%
Sep 05, 2024 11:58 JST
Fujitsu and MoBagel revolutionize business processes through accelerated AI prediction
Sep 05, 2024 10:40 JST
Hitachi Develops a Model of BuilMirai Building IoT Solution for Small and Medium-Sized Buildings to Strengthen Green & Smart Building Business
Sep 04, 2024 12:22 JST
Seven Companies Announce to Conduct Engineering Design Work for Japanese Advanced CCS (Carbon Capture and Storage) Project
Sep 04, 2024 11:46 JST
MHI and Mitsubishi Logisnext to Display "SigmaSynX" Products Enabling Autonomous and Intelligent Warehouse Logistics
Sep 04, 2024 09:48 JST
Cisgenics Brings Next-Generation Irrigation Technology to Australia
Sep 03, 2024 13:29 JST
NEC Launches new system using Biometric Authentication Technology
Sep 03, 2024 10:38 JST
Terrific Texas fight back from TOYOTA GAZOO Racing
Sep 02, 2024 17:09 JST
Eisai Announces Status Relating to Acquisition of Own Shares
Sep 02, 2024 15:12 JST
TANAKA Memorial Foundation to Offer Precious Metals Research Grants of Up to 10 Million Yen (from a Grant Pool of 20 Million Yen)
Sep 02, 2024 11:00 JST
Fujitsu establishes Open All-Photonics Network Lab in Europe to promote global expansion of innovative network infrastructure
Aug 30, 2024 18:15 JST
JCB and Permata Launch the Permata JCB Ultimate Card
Aug 30, 2024 17:00 JST
JCB and BINDO Launch World's First Metal JCB Card
Aug 30, 2024 17:00 JST
Intercity Battery Train Starts Testing in the North of England
Aug 29, 2024 19:20 JST
More Latest Release >>